Jacob P Laubach

29PUBLICATIONS
113CO-AUTHORS
AutoimmunityMedical infection agents (incl. prions)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (29)

|Jun 10, 2025
Single-cell and clonal analysis of AL amyloidosis plasma cells and their bone marrow microenvironment.

Nicolas A Gort-Freitas, Maria Moscvin, Matteo C Da Vià

|Jun 05, 2025
Prospective study of immunogenicity to SARS-CoV-2 booster vaccines in multiple myeloma and Waldenström macroglobulinemia.

Andrew R Branagan, Clifton Mo, Matthew Lei

|Dec 03, 2024
Elotuzumab in combination with pomalidomide, bortezomib, and dexamethasone in relapsed and refractory multiple myeloma.

Andrew J Yee, Jacob P Laubach, Erica L Campagnaro

|Aug 12, 2024
Progression-free survival as a surrogate endpoint in myeloma clinical trials: an evolving paradigm.

Charlotte Pawlyn, Fredrik H Schjesvold, David A Cairns

|Jul 26, 2024
Alliance A061202: ixazomib, pomalidomide, and dexamethasone for patients with lenalidomide-refractory MM in first relapse.

Peter Voorhees, Vera Suman, Yvonne Efebera

|Jul 08, 2024
Daratumumab in transplant-eligible patients with newly diagnosed multiple myeloma: final analysis of clinically relevant subgroups in GRIFFIN.

Ajai Chari, Jonathan L Kaufman, Jacob Laubach

Pageof 5

Frequent Collaborators

19 joint publications

Paul Richardson

4 joint publications

Giada Bianchi

4 joint publications

Larry D Anderson

4 joint publications

Andrew J Yee